Impact of HDAC inhibitors on dendritic cell functions

Experimental Hematology

Volumn 40, Issue 10, 2012, Pages 783-791

  Frikeche, Jihane ^a,b   Peric, Zinaida ^a   Brissot, Eolia ^a,b   Grégoire, Marc ^a   Gaugler, Béatrice ^d,e,f   Mohty, Mohamad ^a,b,c  

^a Team 12   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d RIGHT Interactions Hôte Greffon Tumeur Ingénierie Cellulaire et Génique   (France)

^e UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^f ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BUTYRIC ACID; CD40 LIGAND; CD86 ANTIGEN; DEPSIPEPTIDE; ENTINOSTAT; GIVINOSTAT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; M 344; PANOBINOSTAT; TETRAPEPTIDE; THIOREDOXIN; TRAPOXIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRAFT VERSUS HOST DISEASE; ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER CELL; CELL CONTACT; CELL DEATH; CELL FUNCTION; CUTANEOUS T CELL LYMPHOMA; CYTOKINE RELEASE; DENDRITIC CELL; DIABETES MELLITUS; ENTERITIS; ENZYME INDUCTION; ENZYME INHIBITION; HISTONE ACETYLATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INNATE IMMUNITY; INTESTINE CANCER; LEUKEMIA; LUPUS VULGARIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NATURAL KILLER CELL; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE; UPREGULATION;

ANIMALS; DENDRITIC CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; INFLAMMATION; NEOPLASMS; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 84866323327     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.06.008     Document Type: Review

References (101)

1. Palucka A.K., Ueno H., Fay J., Banchereau J. Dendritic cells: a critical player in cancer therapy?. J Immunother 2008, 31:793-805.
2. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
3. Ohnmacht C., Pullner A., King S.B., et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 2009, 206:549-559.
4. Shortman K., Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002, 2:151-161.
5. Villadangos J.A., Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 2007, 7:543-555.
6. Colonna M., Trinchieri G., Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004, 5:1219-1226.
7. Wollenberg A., Mommaas M., Oppel T., Schottdorf E.M., Gunther S., Moderer M. Expression and function of the mannose receptor CD206 on epidermal dendritic cells in inflammatory skin diseases. J Invest Dermatol 2002, 118:327-334.
8. Gilliet M., Conrad C., Geiges M., et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004, 140:1490-1495.
9. Langlois R.A., Legge K.L. Plasmacytoid dendritic cells enhance mortality during lethal influenza infections by eliminating virus-specific CD8 T cells. J Immunol 2010, 184:4440-4446.
10. Diana J., Griseri T., Lagaye S., et al. NKT cell-plasmacytoid dendritic cell cooperation via OX40 controls viral infection in a tissue-specific manner. Immunity 2009, 30:289-299.
11. Liu Y.J. A unified theory of central tolerance in the thymus. Trends Immunol 2006, 27:215-221.
12. Shortman K., Heath W.R. The CD8+ dendritic cell subset. Immunol Rev 2010, 234:18-31.
13. Merad M., Ginhoux F. Dendritic cell genealogy: a new stem or just another branch?. Nat Immunol 2007, 8:1199-1201.
14. Shortman K., Naik S.H. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007, 7:19-30.
15. Kalinski P., Hilkens C.M., Wierenga E.A., Kapsenberg M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999, 20:561-567.
16. Macatonia S.E., Hosken N.A., Litton M., et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995, 154:5071-5079.
17. Hilkens C.M., Kalinski P., de Boer M., Kapsenberg M.L. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997, 90:1920-1926.
18. Cools N., Ponsaerts P., Van Tendeloo V.F., Berneman Z.N. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol 2007, 82:1365-1374.
19. Probst H.C., Lagnel J., Kollias G., van den Broek M. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity 2003, 18:713-720.
20. Tarbell K.V., Yamazaki S., Olson K., Toy P., Steinman R.M. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004, 199:1467-1477.
21. Watanabe N., Wang Y.H., Lee H.K., Ito T., Cao W., Liu Y.J. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 2005, 436:1181-1185.
22. Yamazaki S., Patel M., Harper A., et al. Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci U S A 2006, 103:2758-2763.
23. McGuirk P., McCann C., Mills K.H. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 2002, 195:221-231.
24. van der Kleij D., Latz E., Brouwers J.F., et al. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J Biol Chem 2002, 277:48122-48129.
25. Steinbrink K., Jonuleit H., Muller G., Schuler G., Knop J., Enk A.H. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999, 93:1634-1642.
26. Sato K., Yamashita N., Baba M., Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003, 18:367-379.
27. Lan Y.Y., Wang Z., Raimondi G., et al. "Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol 2006, 177:5868-5877.
28. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51.
29. Kim S.C., Sprung R., Chen Y., et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 2006, 23:607-618.
30. Redner R.L., Wang J., Liu J.M. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999, 94:417-428.
31. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
32. Yang X.J., Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008, 9:206-218.
33. Yang X.J., Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008, 31:449-461.
34. Walkinshaw D.R., Yang X.J. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 2008, 15:237-243.
35. Mai A., Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009, 41:199-213.
36. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
37. Duvic M., Talpur R., Ni X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
38. Gibson P.R. The intracellular target of butyrate's actions: HDAC or HDON'T?. Gut 2000, 46:447-448.
39. Vezzani A., Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005, 46:1724-1743.
40. Tan J., Cang S., Ma Y., Petrillo R.L., Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010, 3:5.
41. Puccetti E., Zheng X., Brambilla D., et al. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha. Cancer Res 2005, 65:6080-6088.
42. Bali P., Pranpat M., Swaby R., et al. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 2005, 11:6382-6389.
43. Qian D.Z., Ren M., Wei Y., et al. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. Prostate 2005, 64:20-28.
44. Wang X.F., Qian D.Z., Ren M., et al. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 2005, 11:3535-3542.
45. Nebbioso A., Clarke N., Voltz E., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005, 11:77-84.
46. Insinga A., Monestiroli S., Ronzoni S., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005, 11:71-76.
47. Lindemann R.K., Newbold A., Whitecross K.F., et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A 2007, 104:8071-8076.
48. Newbold A., Lindemann R.K., Cluse L.A., Whitecross K.F., Dear A.E., Johnstone R.W. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 2008, 7:1066-1079.
49. Marks P.A., Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005, 4:549-551.
50. Ungerstedt J.S., Sowa Y., Xu W.S., et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005, 102:673-678.
51. Dokmanovic M., Marks P.A. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005, 96:293-304.
52. Srivastava R.K., Kurzrock R., Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 2010, 9:3254-3266.
53. Frew A.J., Lindemann R.K., Martin B.P., et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A 2008, 105:11317-11322.
54. Wang L., de Zoeten E.F., Greene M.I., Hancock W.W. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov 2009, 8:969-981.
55. Shuttleworth S.J., Bailey S.G., Townsend P.A. Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets 2010, 11:1430-1438.
56. Leng C., Gries M., Ziegler J., et al. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol 2006, 34:776-787.
57. Glauben R., Batra A., Stroh T., et al. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut 2008, 57:613-622.
58. Christensen D.P., Dahllof M., Lundh M., et al. HDAC inhibition as a novel treatment for diabetes mellitus. Mol Med 2011, 17:378-390.
59. Choo Q.Y., Ho P.C., Lin H.S. Histone deacetylase inhibitors: new hope for rheumatoid arthritis?. Curr Pharm Des 2008, 14:803-820.
60. Roger T., Lugrin J., Le Roy D., et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011, 117:1205-1217.
61. Caux C., Massacrier C., Vanbervliet B., et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994, 180:1263-1272.
62. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997, 9:10-16.
63. Zhou L.J., Tedder T.F. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci U S A 1996, 93:2588-2592.
64. Kuwano Y., Prazma C.M., Yazawa N., et al. CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells. Int Immunol 2007, 19:977-992.
65. Nencioni A., Beck J., Werth D., et al. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res 2007, 13:3933-3941.
66. Frikeche J., Simon T., Brissot E., Gregoire M., Gaugler B., Mohty M. Impact of valproic acid on dendritic cells function. Immunobiology 2012, 217:704-710.
67. Jung I.D., Lee J.S., Jeong Y.I., et al. Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells. Int J Immunopathol Pharmacol 2009, 22:501-515.
68. Reddy P., Sun Y., Toubai T., et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008, 118:2562-2573.
69. Bode K.A., Schroder K., Hume D.A., et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007, 122:596-606.
70. Brogdon J.L., Xu Y., Szabo S.J., et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007, 109:1123-1130.
71. Song W., Tai Y.T., Tian Z., et al. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 2011, 25:161-168.
72. Reddy P., Maeda Y., Hotary K., et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 2004, 101:3921-3926.
73. Leoni F., Zaliani A., Bertolini G., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 2002, 99:2995-3000.
74. Mellor A.L., Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4:762-774.
75. Sun Y., Chin Y.E., Weisiger E., et al. Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol 2009, 182:5899-5903.
76. Holland S.M., DeLeo F.R., Elloumi H.Z., et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007, 357:1608-1619.
77. Minegishi Y., Saito M., Tsuchiya S., et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448:1058-1062.
78. Barton B.E. STAT3: a potential therapeutic target in dendritic cells for the induction of transplant tolerance. Expert Opin Ther Targets 2006, 10:459-470.
79. Fieschi C., Casanova J.L. The role of interleukin-12 in human infectious diseases: only a faint signature. Eur J Immunol 2003, 33:1461-1464.
80. Uhlig H.H., McKenzie B.S., Hue S., et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006, 25:309-318.
81. Alaibac M., Berti E., Chizzolini C., et al. Role of cellular immunity in the pathogenesis of autoimmune skin diseases. Clin Exp Rheumatol 2006, 24(suppl 40):S14-S19.
82. Edens R.E., Dagtas S., Gilbert K.M. Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int Immunopharmacol 2006, 6:1673-1681.
83. Choo Q.Y., Ho P.C., Tanaka Y., Lin H.S. Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology (Oxford) 2010, 49:1447-1460.
84. Bosisio D., Vulcano M., Del Prete A., et al. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol 2008, 84:1540-1548.
85. Riley J.L., June C.H., Blazar B.R. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009, 30:656-665.
86. Tao R., de Zoeten E.F., Ozkaynak E., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007, 13:1299-1307.
87. Wang L., Tao R., Hancock W.W. Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol Cell Biol 2009, 87:195-202.
88. Akimova T., Ge G., Golovina T., et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 2010, 136:348-363.
89. de Zoeten E.F., Wang L., Sai H., Dillmann W.H., Hancock W.W. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010, 138:583-594.
90. Koenen H.J., Smeets R.L., Vink P.M., van Rijssen E., Boots A.M., Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
91. Reilly C.M., Thomas M., Gogal R., et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J Autoimmun 2008, 31:123-130.
92. Saouaf S.J., Li B., Zhang G., et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 2009, 87:99-104.
93. Kinugasa F., Nagatomi I., Nakanishi T., et al. Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. Transpl Immunol 2009, 21:198-202.
94. Moretta L., Bottino C., Pende D., Castriconi R., Mingari M.C., Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006, 18:151-158.
95. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
96. Zwirner N.W., Domaica C.I. Cytokine regulation of natural killer cell effector functions. Biofactors 2010, 36:274-288.
97. Armeanu S., Bitzer M., Lauer U.M., et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005, 65:6321-6329.
98. Skov S., Pedersen M.T., Andresen L., Straten P.T., Woetmann A., Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005, 65:11136-11145.
99. Rossi L.E., Avila D.E., Spallanzani R.G., et al. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. J Leukoc Biol 2012, 91:321-331.
100. Dinarello C.A., Fossati G., Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med 2011, 17:333-352.
101. Dowdell K.C., Pesnicak L., Hoffmann V., et al. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol 2009, 37:487-494.